Wockhardt receives approval for anti-hypertensive drug

RELATED NEWS Wockhardt opposes Roche patent on Pegasys Wockhardt gets USFDA nod to mkt Ceftriaxone injection Wockhardt Q4 net seen up 18.3% at 67 cr: Sharekhan Wockhardt to launch B-Lift range of dermatology products ALSO READ See latest News about Wockhardt See previous management interviews See what other Experts & Brokerages are saying about Wockhardt Wockhardt BSE | NSE 10/02/12 Are Mutual Funds betting on Wockhardt?

Pharmaceutical and biotechnology major Wockhardt Limited has received approval from the US FDA for marketing Lisinopril in the US market.

 

Lisinopril is used in the treatment of high blood pressure and heart failure. As per IMS, the US market for Lisinopril tablets is about $375 million. With an annual consumption of 3.25 billion tablets, it is the most widely used heart medication in the United States and belongs to the category of ACE (Angiotensin-Converting Enzyme) Inhibitors. Lisinopril is the generic name for the brands Zestril (Astra Zeneca) and Prinivil (Merck & Co.).

 

"Wockhardt has been an active player in the ACE-Inhibitor therapeutic segment and Lisinopril is a logical extension of our capability in this category," said Wockhardt chairman Habil Khorakiwala. "Five FDA approvals in five weeks is a demonstration of Wockhardt's rewarding efforts in the US generics space, which will now go on to further boost our growth in that market."

 

Wockhardt manufactures Lisinopril tablets at its US FDA certified formulation plant at Waluj, Maharashtra. Wockhardt currently markets 18 products in the US, and other new products including Lisinopril tablets will be launched soon.

 

Wockhardt Limited is an internationally approved pharmaceutical and biotechnology company having a strong and innovative research and development programme. Wockhardt has made four successful acquisitions in Europe, where it employs 850 people. It has a wholly-owned subsidiary in USA. Europe and USA together accounts for over half of Wockhardt's sales.

 

Sourced From: Corporate Voice|Weber Shandwick